In general agreement with our findings, examination of the cBioportal database [11, 12] demonstrates TP53 fusions in 68 out of 65,690 samples queried (0.1%), including 24 of 4365 samples (0.6%) of prostatic carcinomas from 4180 patients (accessed 8/14/2018), with prostate carcinomas being the most common tumor type with TP53 fusions (24/68) (Table 1). The gene discussed is TP53; the disease is neoplasm.